News
October 13, 2026: Mounting evidence that popular unapproved peptide causes cancers
Doctors reported that a man who injected the unregulated peptide he purchased at a gym developed a melanoma lesion after only taking the drug for five weeks.
[...]Remembering Alex Boutin: the hidden risks of performance enhancing drugs
Alex took the advice of older gym veterans about how he could bulk up fast, setting off more than a decade of steroid and, eventually, unregulated peptide use.
[...]Update on drug importation, October 2026
Well-meaning advocates continue to propose importing medicine from foreign countries to lower drug prices for Americans. Past efforts didn’t pay off financially and raised public health risks. Here’s the state of this issue today.
[...]October 5, 2026: Two charged in connection with fake Ozempic that spurred FDA public alert
According to court documents, from at least July 2023 to April 2024, the men allegedly obtained the counterfeit products, which included the packaging, pen labels, and needles, from unauthorized sources in China.
[...]September 28, 2026: FDA warns compounding pharmacy for producing “inordinate amounts” of weight loss drugs for identical prescriptions
The Texas-based 503A compounding facility was warned for continuing to manufacture large amounts of weight loss drugs that are “essentially copies” of brand-name products, which is no longer permitted now that shortages have resolved.
[...]September 21, 2026: Pill press bill passes House as owners of LFA Machines arrested
Three senior employees of the pill press company have been arrested as the U.S. House unanimously passes the Stop Pills That Kill Act, which attempts to disrupt the pill press trade.
[...]Statement on FDA’s Warning Letter to Empower Pharmacy for producing drug products in violation of federal law
“Don’t overlook the most consequential finding in this letter. The FDA flagged prescriber determinations that appeared verbatim across hundreds of patient records – like copy-pasted language, pre-loaded for selection, never actually written for an individual patient. The FDA made clear that approach does not meet the bar for prescribing a compounded drug, which must be tailored to the needs of an individual patient.
…
“The FDA must follow this letter with action – seizures and injunctions where warranted – and Congress should work quickly to close the policy gaps that have allowed this shadow drug supply to persist. Patients deserve medicines they can trust.”
September 16, 2026: Third Texas peptide compounder hit with recall
Centric Compounding received nine reports of adverse events related to the injections.
[...]September 8, 2026: Researchers say evidence that peptides are effective “is just not there”
A UCLA Health review of 565 studies on six popular unapproved peptides concluded that marketing claims about peptides are far ahead of the science.
[...]August 31, 2026: Study finds “infrequent inspections” and widespread noncompliance in FDA 503B oversight
The study concludes that the “critical gaps” in oversight pose significant patient safety risks, especially in sterile drug production.
[...]